Venous Therapies

This channel includes news and new technology innovations of Venous Therapies including deep vein thrombosis (DVT) and vena cava filters.

News | Thrombectomy Devices

January 10, 2022 – Akura Medical Inc., a Shifamed portfolio company, announced the closing of its $25 million Series A1 ...

Home January 10, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Venous Therapies

November 22, 2021 — Fewer than 10 days of low-molecular-weight heparin (LMWH) after stenting for extensive iliofemoral ...

Home November 22, 2021
Home
News | Intra-Vascular Ultrasound (IVUS)

November 9 2021 — A new large-scale, real-world analysis of Centers for Medicare and Medicaid Services (CMS) outcomes ...

Home November 09, 2021
Home
News | Vena Cava Filters

July 27, 2021 — The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) to a laser ...

Home July 27, 2021
Home
News | Vascular Closure Devices

July 15, 2021 — Vivasure Medical announced its development program for PerQseal Blue, a sutureless and fully ...

Home July 15, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

June 21, 2021 — The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's dabigatran etexilate ...

Home June 21, 2021
Home
News | EP Lab

May 6, 2021 - Bluegrass Vascular Technologies announced the publication of a report documenting the clinical utility of ...

Home May 06, 2021
Home
Videos | Coronavirus (COVID-19)

Behnood Bikdeli M.D., a cardiologist at the Brigham and Women’s Hospital, Harvard Medical School, Boston, offers an ...

Home April 01, 2021
Home
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis, and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Clotting Prevention in COVID-19 Patients, Thrombosis Prevention in COVID-19 Patients, Preventing blood clots in COVID-19 patients
Feature | Antiplatelet and Anticoagulation Therapies | By Dave Fornell, Editor

A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal ...

Home March 22, 2021
Home
News | Venous Therapies

February 22, 2021 — The U.S. Food and Drug Administration (FDA) recently cleared the Cook Medical Zilver Vena Venous ...

Home February 22, 2021
Home
News | Thrombectomy Devices

January 8, 2021 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Inari Medical Inc ...

Home January 08, 2021
Home
Thrombus formation in the aortic arch in a 46-year-old COVID patients in the ICU. Three trials are underway to find which anticoagulant strategy is best to treat moderate and critically ill patients where COVID-causes venous thrombo-embolism (VTE) is a major cause of complications. Image courtesy of Margarita Revzin et al.
Feature | Coronavirus (COVID-19)

December 23, 2020 — Three clinical trial platforms working together to test the effects of full doses of anticoagulants ...

Home December 23, 2020
Home
News | Venous Therapies

October 26, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Medtronic Abre venous self-expanding ...

Home October 26, 2020
Home
News | Coronavirus (COVID-19)

September 11, 2020 — The National Institutes of Health (NIH) has launched two of three adaptive clinical trials ...

Home September 11, 2020
Home
Subscribe Now